Top Markets
Coin of the day
BerGenBio ASA BerGenBio ASA

BerGenBio ASA

BGBIO
Kedudukan dalam Saham #37880
BerGenBio ASA is a biopharmaceutical firm in the clinical development stage,... BerGenBio ASA is a biopharmaceutical firm in the clinical development stage, focused on developing therapies for drug-resistant, immune-evasive, and metastatic cancers, in addition to respiratory conditions. Its leading compound, Bemcentinib, is a bio-available small molecule AXL inhibitor currently in Phase II clinical trials for major cancer indications and COVID-19. The Phase II trial program specifically addresses non-small cell lung cancer, acute myeloid leukemia, myelodysplastic syndrome, and COVID-19. Moreover, the company is progressing tilvestamab, an anti-AXL antibody, through Phase Ib clinical trials. BerGenBio ASA also maintains a collaboration agreement with Merck & Co. for its clinical studies. The company was founded in 2007 and operates from its base in Bergen, Norway.
Harga Saham
$0.051239
Disegerakkan terakhir: 2025-11-24
Modal Pasaran
$1.38M
Perubahan (1 hari)
-4.48%
Perubahan (1 tahun)
-54.57%
Negara
NO
Perdagangan BerGenBio ASA (BGBIO)

Kategori

Nisbah P/B bagi BerGenBio ASA (BGBIO)
Nisbah P/B pada 2026 TTM: 0
Menurut laporan kewangan dan harga saham terkini BerGenBio ASA, nisbah P/B semasa (TTM) ialah 0. Pada akhir 2026, nisbah P/B syarikat ialah 0.
Sejarah nisbah P/B untuk BerGenBio ASA dari 2026 hingga 2026
Nisbah P/B pada akhir setiap tahun
Tahun Nisbah P/B Ubah
Tidak cukup data untuk tarikh yang disediakan.
Nisbah P/B untuk syarikat atau pesaing yang serupa
Syarikat Nisbah P/B Perbezaan Nisbah P/B Negara
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE